Peregrine Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Peregrine Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-157,671	Closed	-$6.96M	–	343
2025 Q1	$6.96M	Sell	157,671 -3,515	-2%	-$162K	0.23%	124
2024 Q4	$5.82M	Sell	161,186 -4,348	-3%	-$152K	0.17%	188
2024 Q3	$5.3M	Buy	165,534 +28,971	+21%	+$1.08M	0.16%	208
2024 Q2	$5.14M	Buy	136,563 +19,915	+17%	+$838K	0.15%	226
2024 Q1	$5.74M	Sell	116,648 -19,361	-14%	-$895K	0.16%	214
2023 Q4	$4.96M	Sell	136,009 -23,469	-15%	-$613K	0.15%	228
2023 Q3	$3.69M	Sell	159,478 -10,015	-6%	-$274K	0.11%	239
2023 Q2	$4.44M	Sell	169,493 -50	-0%	-$1.31K	0.12%	244
2023 Q1	$4.36M	Buy	169,543 +5,002	+3%	+$146K	0.13%	241
2022 Q4	$4.28M	Buy	+164,541	New	+$4.05M	0.13%	239

Other funds holding SWTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Peregrine Capital Management's SWTX Position: Q2 2025 in Review

Peregrine Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 157,671 shares — an estimated $6.96M sold.

Peregrine Capital Management first reported a position in SWTX in Q4 2022 and held it in 10 quarters. The position peaked at $6.96M in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Peregrine Capital Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Peregrine Capital Management sold 157,671 SpringWorks Therapeutics shares in Q2 2025, an estimated $6.96M.
Peregrine Capital Management first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 10 quarters.
Peregrine Capital Management's SpringWorks Therapeutics position peaked at $6.96M in Q1 2025.
223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Peregrine Capital Management's 13F filing for Q2 2025, filed 1 Aug 2025.